Scientists hunt blood clues to personalize cancer care
NCT ID NCT06947668
Summary
This study aims to find immune system markers in blood, saliva, and stool that can predict how well a different chemotherapy drug works for head and neck cancer patients who cannot take the standard drug. Researchers will analyze samples from 250 patients receiving chemoradiotherapy to see which immune signs are linked to better survival, fewer side effects, and who might benefit from immunotherapy. The goal is to help doctors choose the best treatment for each patient in the future.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARYNX SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universitätsklinikum Erlangen, Strahlenklinik
RECRUITINGErlangen, Bavaria, 91054, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.